Prognostic Value of Time in Blood Pressure Target Range Among Patients With Heart Failure

被引:27
作者
Chen, Kangyu [1 ]
Li, Chao [2 ]
Cornelius, Victoria [3 ]
Yu, Dahai [4 ]
Wang, Qi [1 ]
Shi, Rui [5 ]
Wu, Zhenqiang [6 ]
Su, Hao [1 ]
Yan, Ji [1 ]
Chen, Tao [7 ]
Jiang, Zhixin [8 ]
机构
[1] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Cardiol, Hefei, Peoples R China
[2] Xi An Jiao Tong Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Hlth Sci Ctr, Xian, Peoples R China
[3] Imperial Coll London, Sch Publ Hlth, Imperial Clin Trials Unit, London, England
[4] Keele Univ, Primary Care Ctr Versus Arthrit, Sch Med, Keele, Staffs, England
[5] Imperial Coll London, Royal Brompton & Harefield Natl Hlth Serv Fdn Tru, Heart Rhythm Ctr, Natl Heart & Lung Inst, London, England
[6] Univ Auckland, Dept Geriatr Med, Auckland, New Zealand
[7] Univ Liverpool, Dept Publ Hlth Policy & Syst, Inst Populat Hlth, Whelan Bldg, Liverpool L69 3GB, Merseyside, England
[8] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Dept Cardiol, Nanjing 210029, Peoples R China
关键词
cardiovascular event; heart failure; hypertension; quality of care; time in target range; ALL-CAUSE MORTALITY; CARDIOVASCULAR OUTCOMES; VARIABILITY; MANAGEMENT; TRIAL; SPIRONOLACTONE; ASSOCIATION; PREVENTION; DESIGN; OFFICE;
D O I
10.1016/j.jchf.2022.01.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Blood pressure (BP) is a continuous and dynamic measure. However, standard BP control metrics may not reflect the variability in BP over time. OBJECTIVES This study assessed the prognostic value of time in BP target range among hypertensive patients with heart failure (HF). METHODS The authors performed a post hoc analysis of data from the TOPCAT (Treatment of Preserved Cardiac Function HF with an Aldosterone Antagonist) trial and the BEST (Beta-Blocker Evaluation of Survival Trial). Time in target range (TTR) for each patient was calculated using linear interpolation across the study period with the target range of systolic BP between 120 and 130 mm Hg. RESULTS A total of 4,789 hypertensive patients (n =1,654 from BEST and n = 3,135 from TOPCAT) were included. The cumulative incidences of primary endpoint (ie, cardiovascular death or HF hospitalization) were highest among the top quartile of TTR with a dose-dependent manner across quartiles (P-trend < 0.005). The top quartile of TTR was significantly associated with a lower risk of primary outcome using adjusted Cox regression model (HR: 0.71; 95% CI: 0.60-0.82), cardiovascular mortality (HR: 0.68; 95% CI: 0.55-0.84), HF hospitalization (HR: 0.70; 95% CI: 0.58-0.85), all-cause mortality (HR: 0.69; 95% CI: 0.58-0.83), and any hospitalization (HR: 0.76; 95% CI: 0.67-0.85). Further analyses using restricted cubic spline indicated a linear relationship between TTR and primary outcome. Similar patterns were observed in the individual trial. Sensitivity analyses generated consistent results while redefining target range as 110 to 130 mm Hg for systolic BP or 70 to 80 mm Hg for diastolic BP. CONCLUSIONS TTR could independently predict major adverse cardiovascular events in hypertensive patients with HF. (C) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
引用
收藏
页码:369 / 379
页数:11
相关论文
共 31 条
[11]   Range and Cardiovascular Outcomes in Patients With Hypertension [J].
Fatani, Nayyra ;
Dixon, Dave L. ;
Van Tassell, Benjamin W. ;
Fanikos, John ;
Buckley, Leo F. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (10) :1290-1299
[12]   Dilemmas of Blood Pressure Management for Heart Failure Prevention [J].
Georgiopoulou, Vasiliki V. ;
Kalogeropoulos, Andreas P. ;
Butler, Javed .
CIRCULATION-HEART FAILURE, 2011, 4 (04) :528-+
[13]   Randomised Double-Blind Comparison of Placebo and Active Drugs for Effects on Risks Associated with Blood Pressure Variability in the Systolic Hypertension in Europe Trial [J].
Hara, Azusa ;
Thijs, Lutgarde ;
Asayama, Kei ;
Jacobs, Lotte ;
Wang, Ji-Guang ;
Staessen, Jan A. .
PLOS ONE, 2014, 9 (08)
[14]   Blood pressure control and improved cardiovascular outcomes in the international verapamil SR-trandolapril study [J].
Mancia, Giuseppe ;
Messerli, Franz ;
Bakris, George ;
Zhou, Qian ;
Champion, Annette ;
Pepine, Carl J. .
HYPERTENSION, 2007, 50 (02) :299-305
[15]   Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction [J].
McMurray, J. J. V. ;
Solomon, S. D. ;
Inzucchi, S. E. ;
Kober, L. ;
Kosiborod, M. N. ;
Martinez, F. A. ;
Ponikowski, P. ;
Sabatine, M. S. ;
Anand, I. S. ;
Belohlavek, J. ;
Bohm, M. ;
Chiang, C. -E. ;
Chopra, V. K. ;
de Boer, R. A. ;
Desai, A. S. ;
Diez, M. ;
Drozdz, J. ;
Dukat, A. ;
Ge, J. ;
Howlett, J. G. ;
Katova, T. ;
Kitakaze, M. ;
Ljungman, C. E. A. ;
Merkely, B. ;
Nicolau, J. C. ;
O'Meara, E. ;
Petrie, M. C. ;
Vinh, P. N. ;
Schou, M. ;
Tereshchenko, S. ;
Verma, S. ;
Held, C. ;
DeMets, D. L. ;
Docherty, K. F. ;
Jhund, P. S. ;
Bengtsson, O. ;
Sjostrand, M. ;
Langkilde, A. -M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :1995-2008
[16]   Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure [J].
McMurray, John J. V. ;
Packer, Milton ;
Desai, Akshay S. ;
Gong, Jianjian ;
Lefkowitz, Martin P. ;
Rizkala, Adel R. ;
Rouleau, Jean L. ;
Shi, Victor C. ;
Solomon, Scott D. ;
Swedberg, Karl ;
Zile, Michael R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :993-1004
[17]  
Messerli Franz H, 2017, JACC Heart Fail, V5, P543, DOI 10.1016/j.jchf.2017.04.012
[18]   The Relationship Between Visit-to-Visit Variability in Systolic Blood Pressure and All-Cause Mortality in the General Population Findings From NHANES III, 1988 to 1994 [J].
Muntner, Paul ;
Shimbo, Daichi ;
Tonelli, Marcello ;
Reynolds, Kristi ;
Arnett, Donna K. ;
Oparil, Suzanne .
HYPERTENSION, 2011, 57 (02) :160-166
[19]  
Nichols GA, 2015, AM J CARDIOL, V116, P1088, DOI [10.1016/j.amjcard.2015.07.018, 10.5935/2359-4802.20160060]
[20]   Blood pressure and heart failure [J].
Oh, Gyu Chul ;
Cho, Hyun-Jai .
CLINICAL HYPERTENSION, 2020, 26 (01)